kicked off on Tuesday, with Jazz Pharmaceuticals plc (NASDAQ: JAZZ) stock price down -0.83% from the previous day of trading, before settling in for the closing price of $108.52. JAZZ’s price has ranged from $99.06 to $137.38 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 15.52%. Meanwhile, its annual earnings per share averaged 6.75%. With a float of $59.62 million, this company’s outstanding shares have now reached $62.26 million.
Considering the fact that the conglomerate employs 2800 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 77.56%, operating margin of 16.63%, and the pretax margin is 7.61%.
Jazz Pharmaceuticals plc (JAZZ) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Jazz Pharmaceuticals plc is 3.45%, while institutional ownership is 94.87%. The most recent insider transaction that took place on Sep 06 ’24, was worth 152,703. In this transaction SVP, Technical Operations of this company sold 1,410 shares at a rate of $108.30, taking the stock ownership to the 14,531 shares. Before that another transaction happened on Sep 06 ’24, when Company’s Officer proposed sale 2,691 for $110.00, making the entire transaction worth $296,010.
Jazz Pharmaceuticals plc (JAZZ) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 6.75% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.49% during the next five years compared to -3.53% drop over the previous five years of trading.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Trading Performance Indicators
Here are Jazz Pharmaceuticals plc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.70. Likewise, its price to free cash flow for the trailing twelve months is 6.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 5.60, a number that is poised to hit 5.53 in the next quarter and is forecasted to reach 21.52 in one year’s time.
Technical Analysis of Jazz Pharmaceuticals plc (JAZZ)
Compared to the last year’s volume of 0.68 million, its volume of 0.47 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 26.74%. Additionally, its Average True Range was 2.56.
During the past 100 days, Jazz Pharmaceuticals plc’s (JAZZ) raw stochastic average was set at 45.75%, which indicates a significant increase from 12.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 18.70% in the past 14 days, which was lower than the 26.46% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $110.80, while its 200-day Moving Average is $113.98. Nevertheless, the first resistance level for the watch stands at $108.70 in the near term. At $109.78, the stock is likely to face the second major resistance level. The third major resistance level sits at $110.72. If the price goes on to break the first support level at $106.68, it is likely to go to the next support level at $105.74. Now, if the price goes above the second support level, the third support stands at $104.66.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Key Stats
With a market capitalization of 6.65 billion, the company has a total of 63,062K Shares Outstanding. Currently, annual sales are 3,834 M while annual income is 414,830 K. The company’s previous quarter sales were 1,024 M while its latest quarter income was 168,570 K.
